Skip to Content

Kazano Approval History

FDA Approved: Yes (First approved January 25, 2013)
Brand name: Kazano
Generic name: alogliptin and metformin
Dosage form: Tablets
Company: Takeda Pharmaceutical Company Limited
Treatment for: Diabetes, Type 2

Kazano (alogliptin and metformin) is a dipeptidyl peptidase-4 (DPP-4) inhibitor and biguanide antihyperglycemic fixed-dose combination for the treatment of type 2 diabetes.

Development History and FDA Approval Process for Kazano

DateArticle
Jan 25, 2013Approval Takeda Receives FDA Approval for Kazano (alogliptin and metformin) for Type 2 Diabetes
Nov 28, 2011Takeda Submits New Drug Application in the U.S. for Investigational Type 2 Diabetes Therapy, Fixed-Dose Combination Alogliptin/Metformin

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide